These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 38867291

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Targeting endothelial glycolytic reprogramming by tsRNA-1599 for ocular anti-angiogenesis therapy.
    Han XY, Kong LJ, Li D, Tong M, Li XM, Zhao C, Jiang Q, Yan B.
    Theranostics; 2024; 14(9):3509-3525. PubMed ID: 38948065
    [Abstract] [Full Text] [Related]

  • 3. Apatinib, an Inhibitor of Vascular Endothelial Growth Factor Receptor 2, Suppresses Pathologic Ocular Neovascularization in Mice.
    Kim KL, Suh W.
    Invest Ophthalmol Vis Sci; 2017 Jul 01; 58(9):3592-3599. PubMed ID: 28715845
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Antiangiogenic effect of dasatinib in murine models of oxygen-induced retinopathy and laser-induced choroidal neovascularization.
    Seo S, Suh W.
    Mol Vis; 2017 Jul 01; 23():823-831. PubMed ID: 29225458
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Exosome-mediated delivery of an anti-angiogenic peptide inhibits pathological retinal angiogenesis.
    Dong X, Lei Y, Yu Z, Wang T, Liu Y, Han G, Zhang X, Li Y, Song Y, Xu H, Du M, Yin H, Wang X, Yan H.
    Theranostics; 2021 Jul 01; 11(11):5107-5126. PubMed ID: 33859737
    [Abstract] [Full Text] [Related]

  • 9. Suppression of Pathological Ocular Neovascularization by a Small Molecular Multi-Targeting Kinase Inhibitor, DCZ19903.
    Ding J, Li B, Zhang H, Xu Z, Zhang Q, Ye R, Feng S, Jiang Q, Zhu W, Yan B.
    Transl Vis Sci Technol; 2022 Dec 01; 11(12):8. PubMed ID: 36484641
    [Abstract] [Full Text] [Related]

  • 10. Acrizanib as a Novel Therapeutic Agent for Fundus Neovascularization via Inhibitory Phosphorylation of VEGFR2.
    Tang X, Cui K, Wu P, Hu A, Fan M, Lu X, Yang F, Lin J, Yu S, Xu Y, Liang X.
    Transl Vis Sci Technol; 2024 Jan 02; 13(1):1. PubMed ID: 38165719
    [Abstract] [Full Text] [Related]

  • 11. Nonpeptide somatostatin receptor agonists specifically target ocular neovascularization via the somatostatin type 2 receptor.
    Palii SS, Afzal A, Shaw LC, Pan H, Caballero S, Miller RC, Jurczyk S, Reubi JC, Tan Y, Hochhaus G, Edelhauser H, Geroski D, Shapiro G, Grant MB.
    Invest Ophthalmol Vis Sci; 2008 Nov 02; 49(11):5094-102. PubMed ID: 18599562
    [Abstract] [Full Text] [Related]

  • 12. Newly Identified Peptide, Peptide Lv, Promotes Pathological Angiogenesis.
    Shi L, Zhao M, Abbey CA, Tsai SH, Xie W, Pham D, Chapman S, Bayless KJ, Hein TW, Rosa RH, Ko ML, Kuo L, Ko GY.
    J Am Heart Assoc; 2019 Nov 19; 8(22):e013673. PubMed ID: 31698979
    [Abstract] [Full Text] [Related]

  • 13. Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects.
    Li D, Xie K, Zhang L, Yao X, Li H, Xu Q, Wang X, Jiang J, Fang J.
    Cancer Lett; 2016 Jul 28; 377(2):164-73. PubMed ID: 27130666
    [Abstract] [Full Text] [Related]

  • 14. Novel peptide derived from IGF-2 displays anti-angiogenic activity in vitro and inhibits retinal angiogenesis in a model of oxygen-induced retinopathy.
    Zheng Y, Sun Q, Xu X, Wang W.
    Clin Exp Ophthalmol; 2020 Dec 28; 48(9):1261-1275. PubMed ID: 33026147
    [Abstract] [Full Text] [Related]

  • 15. Antagonist of nucleolin, N6L, inhibits neovascularization in mouse models of retinopathies.
    Darche M, Cossutta M, Caruana L, Houppe C, Gilles ME, Habert D, Guilloneau X, Vignaud L, Paques M, Courty J, Cascone I.
    FASEB J; 2020 Apr 28; 34(4):5851-5862. PubMed ID: 32141122
    [Abstract] [Full Text] [Related]

  • 16. Pathogenic role and therapeutic potential of pleiotrophin in mouse models of ocular vascular disease.
    Wang W, LeBlanc ME, Chen X, Chen P, Ji Y, Brewer M, Tian H, Spring SR, Webster KA, Li W.
    Angiogenesis; 2017 Nov 28; 20(4):479-492. PubMed ID: 28447229
    [Abstract] [Full Text] [Related]

  • 17. Endothelial TWIST1 promotes pathological ocular angiogenesis.
    Li J, Liu CH, Sun Y, Gong Y, Fu Z, Evans LP, Tian KT, Juan AM, Hurst CG, Mammoto A, Chen J.
    Invest Ophthalmol Vis Sci; 2014 Nov 20; 55(12):8267-77. PubMed ID: 25414194
    [Abstract] [Full Text] [Related]

  • 18. Circular RNA-ZBTB44 regulates the development of choroidal neovascularization.
    Zhou RM, Shi LJ, Shan K, Sun YN, Wang SS, Zhang SJ, Li XM, Jiang Q, Yan B, Zhao C.
    Theranostics; 2020 Nov 20; 10(7):3293-3307. PubMed ID: 32194869
    [Abstract] [Full Text] [Related]

  • 19. Imidazole-based alkaloid derivative LCB54-0009 suppresses ocular angiogenesis and lymphangiogenesis in models of experimental retinopathy and corneal neovascularization.
    Kim BH, Lee J, Choi JS, Park DY, Song HY, Park TK, Cho CH, Ye SK, Joo CK, Koh GY, Kim TY.
    Br J Pharmacol; 2015 Aug 20; 172(15):3875-89. PubMed ID: 25917462
    [Abstract] [Full Text] [Related]

  • 20. Secretogranin III as a novel target for the therapy of choroidal neovascularization.
    LeBlanc ME, Wang W, Ji Y, Tian H, Liu D, Zhang X, Li W.
    Exp Eye Res; 2019 Apr 20; 181():120-126. PubMed ID: 30633921
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.